Array BioPharma Inc. (ARRY) Drops 9.97% on February 08

Equities Staff |

Array BioPharma Inc. (ARRY) was one of the Russell 2000's biggest losers for Monday February 08 as the stock slid 9.97% to $2.62, a loss of $-0.29 per share. Starting at an opening price of $2.88 a share, the stock traded between $2.59 and $2.94 over the course of the trading day. Volume was 2.45 million shares over 12,940 trades, against an average daily volume of 2.77 million shares and a total float of 142.62 million.

The losses send Array BioPharma Inc. down to a market cap of $373.66 million. In the last year, Array BioPharma Inc. has traded between $8.59 and $2.78, and its 50-day SMA is currently $3.73 and 200-day SMA is $5.52.

Array BioPharma Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases.

Array BioPharma Inc. is based out of Boulder, CO and has some 156 employees. Its CEO is Ron Squarer.

For a complete fundamental analysis analysis of Array BioPharma Inc., check out’s Stock Valuation Analysis report for ARRY. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Beleave Inc.

Beleave Inc is a biotech company. The Company is engaged in the production of medical marijuana under the Marihuana for Medical Purposes Regulations outlined by Health Canada.

Private Markets

Dropbox, Inc.

Dropbox is a service that allows their users to bring all photos, docs, and videos anywhere, and share them easily. Any file saved to Dropbox will automatically save to all…

Santo Diablo Mezcal

Santo Diablo Mezcal has been created to capitalize on a boom sector of the beverage market currently full of many small unmemorable products by producing one sexy, household, easily recognizable…